A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies

Cancer

Volumn 117, Issue 24, 2011, Pages 5548-5559

  Wuthrick, Evan J ^a   Kamrava, Mitchell ^b   Curran Jr , Walter J ^a   Werner Wasik, Maria ^a   Camphausen, Kevin A ^b   Hyslop, Terry ^c   Axelrod, Rita ^a   Andrews, David W ^a   Glass, Jon ^a   MacHtay, Mitchell ^a   Dicker, Adam P ^a,d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

antiangiogenesis; brain metastases; central nervous system; radiation therapy; sunitinib

Indexed keywords

GELATINASE A; GELATINASE B; SCATTER FACTOR RECEPTOR; SUNITINIB; VASCULOTROPIN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER GROWTH; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM METASTASIS; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DERMATITIS; DIARRHEA; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; DYSPHASIA; DYSPNEA; EDEMA; EPISTAXIS; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERBILIRUBINEMIA; HYPERCAPNIA; HYPERGLYCEMIA; HYPERSALIVATION; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPROTEINEMIA; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN URINE LEVEL; RADIATION DOSE; SEIZURE; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UREMIA; VAGINA BLEEDING; VOMITING;

AGED; ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INDOLES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PYRROLES; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 82955237229     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26216     Document Type: Article

References (56)

1. Jain RK,. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307: 58-62. (Pubitemid 40093472)
2. Jain RK,. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001; 7: 987-989. (Pubitemid 32937367)
3. Wachsberger P, Burd R, Dicker AP,. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res. 2003; 9: 1957-1971. (Pubitemid 36687614)
4. Wachsberger P, Burd R, Dicker AP,. Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. Hematol Oncol Clin North Am. 2004; 18: 1039-1057, viii. (Pubitemid 39335758)
5. Lee CG, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000; 60: 5565-5570.
6. Dewhirst MW, Cao Y, Moeller B,. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008; 8: 425-437. (Pubitemid 351744964)
7. Shinohara ET, Cao C, Niermann K, et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene. 2005; 24: 5414-5422. (Pubitemid 43080085)
8. Li B, Sharpe EE, Maupin AB, et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J. 2006; 20: 1495-1497.
9. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science. 2006; 313: 1785-1787. (Pubitemid 44454154)
10. Su Y, Zheng L, Wang Q, Bao J, Cai Z, Liu A,. The PI3K/Akt pathway up-regulates Id1 and integrin alpha4 to enhance recruitment of human ovarian cancer endothelial progenitor cells [serial online]. BMC Cancer. 2010; 10: 459.
11. de Bouard S, Herlin P, Christensen JG, et al. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol. 2007; 9: 412-423.
12. Milker-Zabel S, Bois AZ, Ranai G, et al. SU11657 enhances radiosensitivity of human meningioma cells. Int J Radiat Oncol Biol Phys. 2008; 70: 1213-1218.
13. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM,. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003; 2: 471-478.
14. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther. 2003; 2: 1011-1021.
15. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D,. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003; 111: 1287-1295. (Pubitemid 36554699)
16. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A. 2005; 102: 11011-11016. (Pubitemid 41105984)
17. Laird AD, Cherrington JM,. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin Investig Drugs. 2003; 12: 51-64. (Pubitemid 36104643)
18. Marzola P, Degrassi A, Calderan L, et al. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res. 2005; 11: 5827-5832. (Pubitemid 41170309)
19. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9: 327-337. (Pubitemid 36109749)
20. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003; 101: 3597-3605. (Pubitemid 36857948)
21. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003; 46: 1116-1119. (Pubitemid 36428215)
22. Yee KW, Schittenhelm M, O'Farrell AM, et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood. 2004; 104: 4202-4209. (Pubitemid 39620175)
23. Geng L, Donnelly E, McMahon G, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 2001; 61: 2413-2419. (Pubitemid 32685816)
24. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999; 59: 3374-3378. (Pubitemid 29334495)
25. Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW,. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res. 2002; 62: 1702-1706. (Pubitemid 34408492)
26. Hess C, Vuong V, Hegyi I, et al. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer. 2001; 85: 2010-2016. (Pubitemid 34775341)
27. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD,. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 2001; 61: 39-44. (Pubitemid 32095696)
28. Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 2003; 63: 4009-4016. (Pubitemid 36917920)
29. Cuneo KC, Geng L, Fu A, Orton D, Hallahan DE, Chakravarthy AB,. SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys. 2008; 71: 873-879. (Pubitemid 351749533)
30. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649-655. (Pubitemid 13149996)
31. National Cancer Institute, Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events version 3.0 (CTCAEv3), vol. 2008; 2006. Accessed December 1, 2010.
32. Escudier B, Roigas J, Gillessen S, et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 4068-4075.
33. Srinivas S, Roigas J, Gillessen S, et al. Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): updated results [abstract]. J Clin Oncol. 2007; 25 (18S). Abstract 5040.
34. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009; 45: 1959-1968.
35. George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009; 27: 3154-3160.
36. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC,. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst. 1997; 89: 1138-1147. (Pubitemid 27337928)
37. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG,. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8: 1277-1280. (Pubitemid 20195640)
38. Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA,. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res. 2008; 14: 2378-2386. (Pubitemid 351551071)
39. Chan LW, Moses MA, Goley E, et al. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol. 2004; 22: 499-506. (Pubitemid 41079780)
40. Athauda G, Giubellino A, Coleman JA, et al. c-Met ectodomain shedding rate correlates with malignant potential. Clin Cancer Res. 2006; 12 (14 pt 1): 4154-4162.
41. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
42. Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins [serial online]. J Transl Med. 2007; 5: 32.
43. Knisely JP, Berkey B, Chakravarti A, et al. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys. 2008; 71: 79-86.
44. Suh JH, Stea B, Nabid A, et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol. 2006; 24: 106-114. (Pubitemid 46630501)
45. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with 1 to 3 brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004; 363: 1665-1672. (Pubitemid 38670323)
46. Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003; 21: 2529-2536. (Pubitemid 46606335)
47. Kao J, Packer S, Vu HL, et al. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer. 2009; 115: 3571-3580.
48. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004; 6: 553-563. (Pubitemid 40017699)
49. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007; 11: 83-95. (Pubitemid 46075199)
50. Pouessel D, Culine S,. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol. 2008; 53: 376-381. (Pubitemid 350296582)
51. Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009; 75: 156-163.
52. Heymach JV, Desai J, Manola J, et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res. 2004; 10: 5732-5740. (Pubitemid 39180949)
53. Norden-Zfoni A, Desai J, Manola J, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res. 2007; 13: 2643-2650. (Pubitemid 46788031)
54. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in 3 Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997; 37: 745-751. (Pubitemid 27181303)
55. Khuntia D, Brown P, Li J, Mehta MP,. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol. 2006; 24: 1295-1304. (Pubitemid 46622033)
56. Sundstrom JT, Minn H, Lertola KK, Nordman E,. Prognosis of patients treated for intracranial metastases with whole-brain irradiation. Ann Med. 1998; 30: 296-299. (Pubitemid 28306455)